Oxycodone

Generic Name
Oxycodone
Brand Names
Endocet, Endodan Reformulated May 2009, Nalocet, Oxaydo, Oxy.IR, Oxycontin, Oxyneo, Percocet, Prolate, Rivacocet, Roxicet, Roxicodone, Roxybond, Targin, Targiniq, Xolox, Xtampza
Drug Type
Small Molecule
Chemical Formula
C18H21NO4
CAS Number
76-42-6
Unique Ingredient Identifier
CD35PMG570
Background

Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, wa...

Indication

Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.

Associated Conditions
Severe Acute Pain, Severe Pain, Severe, Chronic Pain, Acute, moderate Pain, Chronic, moderate Pain
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

Phase 3
Terminated
Conditions
Severe Caner Pain
First Posted Date
2008-02-29
Last Posted Date
2018-10-24
Lead Sponsor
Mundipharma Research Limited
Target Recruit Count
33
Registration Number
NCT00626600
Locations
🇬🇧

Royal Marsden Hospital, London, United Kingdom

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

First Posted Date
2008-02-13
Last Posted Date
2014-05-09
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
901
Registration Number
NCT00613938

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

First Posted Date
2007-08-09
Last Posted Date
2018-10-23
Lead Sponsor
Mundipharma Research GmbH & Co KG
Target Recruit Count
230
Registration Number
NCT00513656
Locations
🇬🇧

Dr S Ahmedzai, Sheffield, United Kingdom

Effects of Garlic Supplements on Opioids in Healthy Volunteers

First Posted Date
2007-07-11
Last Posted Date
2017-04-07
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
15
Registration Number
NCT00499460
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Phase 4
Terminated
Conditions
Osteoarthritis
Interventions
Drug: placebo
Drug: celecoxib
Drug: Oxycodone
First Posted Date
2007-06-11
Last Posted Date
2021-04-14
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT00484718
Locations
🇺🇸

VAPAHCS, Palo Alto, California, United States

🇺🇸

Stanford University, Stanford, California, United States

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Phase 2
Terminated
Conditions
Osteoarthritis
Interventions
Drug: Placebo
Drug: PF-000592379
Drug: Oxycodone
First Posted Date
2007-06-08
Last Posted Date
2011-04-29
Lead Sponsor
Pfizer
Target Recruit Count
113
Registration Number
NCT00483977
Locations
🇺🇸

Pfizer Investigational Site, Richmond, Virginia, United States

Tapentadol (CG5503)

First Posted Date
2007-01-15
Last Posted Date
2012-04-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1030
Registration Number
NCT00421928

Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain

First Posted Date
2006-09-21
Last Posted Date
2013-08-02
Lead Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Target Recruit Count
30
Registration Number
NCT00378937

OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models

Phase 4
Completed
Conditions
Healthy
First Posted Date
2006-01-04
Last Posted Date
2007-01-30
Lead Sponsor
Odense University Hospital
Target Recruit Count
32
Registration Number
NCT00271973
Locations
🇩🇰

University of Southern Denmark, IST Clinical Pharmacology, Odense, Odense C, Denmark

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Phase 3
Completed
Conditions
Pain
Interventions
Drug: Oxycodone
Drug: OROS hydromorphone HCl
First Posted Date
2005-12-05
Last Posted Date
2014-06-03
Lead Sponsor
Janssen Pharmaceutica N.V., Belgium
Target Recruit Count
504
Registration Number
NCT00261495
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy